Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK2 | O96017 | 14/20 | 0.77 |
| ▸ | SCD | O00767 | 3/20 | 0.67 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | THRB | P10828 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2318980 | 0.87 | CHEK2 (1.00) | CHEK2NR4A2 | |
| SCHEMBL2316768 | 0.87 | SCD (0.59) | CHEK2SCDMEN1THRBKMT2A | |
| SCHEMBL2802771 | 0.86 | SIRT2 (0.71) | CHEK2SCD | |
| SCHEMBL6645851 | 0.85 | CHEK2 (1.00) | CHEK2MEN1THRBKMT2A | |
| SCHEMBL2321478 | 0.84 | CHEK2 (0.72) | CHEK2SCDNR4A2 | |
| SCHEMBL3178116 | 0.81 | CHEK2 (0.78) | CHEK2NR4A2KMT2A | |
| SCHEMBL20982644 | 0.81 | NR4A2 (0.86) | CHEK2NR4A2KMT2A | |
| SCHEMBL6643584 | 0.81 | CHEK2 (1.00) | CHEK2NR4A2 | |
| SCHEMBL3178995 | 0.80 | CHEK2 (0.97) | CHEK2NR4A2MEN1THRBKMT2A | |
| SCHEMBL2315701 | 0.80 | SCD (0.56) | CHEK2SCD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2183222-B1 | AZOLORAINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, PHARMACEUTICALS CONTAINING THESE COMPOUNDS, AND THE USE THEREOF | SANOFI SA (FR) | 2011-08-03 | — | — | EP | disclosed |
| US-20100240580-A1 | AZOLOARINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, PHARMACEUTICALS CONTAINING THESE COMPOUNDS AND THE USE THEREOF | SANOFI-AVENTIS (FR) | 2010-09-23 | — | — | US | disclosed |
| EP-2183222-A2 | AZOLORAINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, PHARMACEUTICALS CONTAINING THESE COMPOUNDS, AND THE USE THEREOF | Sanofi-Aventis (FR) | 2010-05-12 | — | — | EP | disclosed |
| WO-2009024287-A2 | AZOLORAINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, PHARMACEUTICALS CONTAINING THESE COMPOUNDS, AND THE USE THEREOF | SANOFI-AVENTIS (FR) | 2009-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240580-A1 | AZOLOARINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, PHARMACEUTICALS CONTAINING THESE COMPOUNDS AND THE USE THEREOF | CYP3A43, CYP11B1, CYP11B2 | CHEK2 3959/4885SCD 3183/4885NR4A2 2260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.